ASSESSMENT OF GONADOTROPIN-RELEASING HORMONE LEVELS IN OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME

Abstract

Gonadotropin-releasing hormone (GnRH) is one of the major hormones affecting the reproductive system, and when elevated, it leads to polycystic ovarian syndrome. Obesity is a main cause of GnRH elevation. A current study was conducted from October to December 2024 and included 100 samples from Iraqi women diagnosed with polycystic ovary syndrome (PCOS), collected from the Infertility Center at Al-Sadder Medical City and Al-Zahraa Teaching Hospital, alongside 100 samples from healthy women. The concentration of GnRH was measured using an enzyme-linked immunosorbent assay (ELISA) kit to evaluate variations in this biochemical parameter between healthy individuals and PCOS patients. Statistical analysis was performed using a P-value test (P < 0.05) to assess the significance of the study results. GnRH concentrations were elevated in PCOS patients compared to the control group. Significant differences (P < 0.05) were observed between the two groups, with a P-value of 0.0001. In conclusion, GnRH levels were elevated in PCOS patients when compared with healthy individuals, so GnRH highly associated with the occurrence of PCOS and contribute to hormonal disorders.

Keywords:

Gonadotropin Releasing Hormone, Polycystic Ovary Syndrome , Obesity

References

Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol. 2012;19(7):594-601. doi:10.1111/j.1442-2042.2012.02997.x

Perrett RM, McArdle CA. Molecular mechanisms of gonadotropin-releasing hormone signaling: integrating cyclic nucleotides into the network. Front Endocrinol (Lausanne). 2013;4:180. Published 2013 Nov 20. doi:10.3389/fendo.2013.00180

Stamatiades GA, Kaiser UB. Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression. Mol Cell Endocrinol. 2018;463:131-141. doi:10.1016/j.mce.2017.10.015

Lettieri A, Oleari R, van den Munkhof MH, et al. SEMA6A drives GnRH neuron-dependent puberty onset by tuning median eminence vascular permeability. Nat Commun. 2023;14(1):8097. Published 2023 Dec 7. doi:10.1038/s41467-023-43820-z

Chaudhari N, Dawalbhakta M, Nampoothiri L. GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. Reprod Biol Endocrinol. 2018;16(1):37. Published 2018 Apr 11. doi:10.1186/s12958-018-0354-x

McCartney, C. R., & Campbell, R. E. (2020). Abnormal GnRH pulsatility in polycystic ovary syndrome: recent insights. Current opinion in endocrine and metabolic research, 12, 78-84.‏

McCartney, C. R., Campbell, R. E., Marshall, J. C., & Moenter, S. M. (2022). The role of gonadotropin‐releasing hormone neurons in polycystic ovary syndrome. Journal of neuroendocrinology, 34(5), e13093.‏

Thualfiqar Ghalib Turki, Jumana Waleed Ammar "Role of Gonadotropin-Releasing Hormone, Leptin Hormone, Luteinizing Hormone, Follicle-Stimulating Hormone, and Obesity in Polycystic Ovarian Syndrome." International Journal of Scientific Research in Biological Sciences 11.4 (2024): 1-6.

McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome. N Engl J Med. 2016;375(1):54-64. doi:10.1056/NEJMcp1514916

Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2021;95(4):531-541. doi:10.1111/cen.14421

Christensen SB, Black MH, Smith N, et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril. 2013;100(2):470-477. doi:10.1016/j.fertnstert.2013.04.001

Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome [published correction appears in Lancet Diabetes Endocrinol. 2022 Nov;10(11):e11. doi: 10.1016/S2213-8587(22)00281-9]. Lancet Diabetes Endocrinol. 2022;10(9):668-680. doi:10.1016/S2213-8587(22)00163-2

Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020;35:100937. doi:10.1016/j.molmet.2020.01.001

Deswal R, Nanda S, Dang AS. Association of Luteinizing hormone and LH receptor gene polymorphism with susceptibility of Polycystic ovary syndrome. Syst Biol Reprod Med. 2019;65(5):400-408. doi:10.1080/19396368.2019.1595217

Crisosto N, Ladrón de Guevara A, Echiburú B, et al. Higher luteinizing hormone levels associated with antimüllerian hormone in postmenarchal daughters of women with polycystic ovary syndrome. Fertil Steril. 2019;111(2):381-388. doi:10.1016/j.fertnstert.2018.10.011

Cadagan D, Khan R, Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod Biol. 2016;16(1):53-60. doi:10.1016/j.repbio.2015.12.006

Laven JSE. Follicle Stimulating Hormone Receptor (FSHR) Polymorphisms and Polycystic Ovary Syndrome (PCOS). Front Endocrinol (Lausanne). 2019;10:23. Published 2019 Feb 12. doi:10.3389/fendo.2019.00023

Saadia Z. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women. Med Arch. 2020;74(4):289-293. doi:10.5455/medarh.2020.74.289-293

Constantin S, Bjelobaba I, Stojilkovic SS. Pituitary gonadotroph-specific patterns of gene expression and hormone secretion. Curr Opin Pharmacol. 2022;66:102274. doi:10.1016/j.coph.2022.102274

Oduwole OO, Huhtaniemi IT, Misrahi M. The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited. Int J Mol Sci. 2021;22(23):12735. Published 2021 Nov 25. doi:10.3390/ijms222312735

Wang, B., & Li, Z. (2023). Hypersecretion of basal luteinizing hormone and an increased risk of pregnancy loss among women with polycystic ovary syndrome undergoing controlled ovarian stimulation and intrauterine insemination. Heliyon, 9(5).‏